Assessment of mediastinal mass Assessment of mediastinal mass - Differential diagnosis of symptoms | BMJ Best PracticeSkip to main contentSkip to search * English (US)EnglishPortuguês * Log in * Personal account * Access through your institution(Open Athens) * Subscribe * Access through your institution * Log in * English (US)EnglishPortuguês HomeSearchSearchHome * About usOverviewWhat is BMJ of effectiveness Global impactCustomer stories * Browse clinical contentRecent updatesSpecialtiesTry a free topicPatient informationVideosCalculators * What’s newClinical updatesNewsPodcast * AccessLog in via...Personal subscription or user profileAccess through your institutionAccess codeSubscribeFree trialHow do I get access?Download the app * HelpFAQsHow do I get access?Contact us Assessment of mediastinal
Lisocabtagene Maraleucel (Breyanzi) - For the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBCL), and DLBCL arising f View of Lisocabtagene Maraleucel (Breyanzi) | Canadian Journal of Health Technologies Return to Article DetailsLisocabtagene Maraleucel
Lisocabtagene maraleucel (Breyanzi) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B) ENGLISH | DEUTSCH ATOM RSS 1.0 RSS 2.0SIMPLE SEARCHADVANCED SEARCHHELPSERVICESLOGINBrowseTypeSubjectAuthor / EditorInstitutionYear AIHTA - Publications - Search - Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)Rothschedl, E. and Wolf, S. (2023): Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal
Lisocabtagene maraleucel (Breyanzi) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B) Lisocabtagene maraleucel (Breyanzi®) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update May 2022 - Repository of AIHTA GmbH English | Deutsch Atom RSS 1.0 RSS 2.0 * Simple search * Advanced search * Help * Services * Login * Browse * Type * Subject * Author / Editor * Institution * YearAIHTA - Publications - Search - Lisocabtagene maraleucel (Breyanzi®) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal
Oncology Emergencies. 1. Management of Tumour Lysis Syndrome 2. Management of Hyperleukocytosis 3. Anterior Mediastinal Mass Printed copies of this document may not be up to date, obtain the most recent version from www.cats.nhs.uk Children’s Acute Transport Service provides paediatric intensive care retrieval for Great Ormond Street, The Royal Brompton and St Mary’s NHS Trusts. Funded and accountable to the North Thames Paediatric Intensive Care Commissioning Group through Great Ormond Street NHS Trust. Page 1 of 8 Children’s Acute Transport Service Clinical Guidelines Oncology Emergencies 1. Management of Tumour Lysis Syndrome 2. Management of Hyperleukocytosis 3. Anterior Mediastinal Mass Document Control Information Author M O’Connor Author Position CATS
Mediastinal Shift Index: A Novel Postnatal Measurement of Mediastinal Movement that Predicts Survival in Neonates With Congenital Diaphragmatic Hernia on Extracorporeal Membrane Oxygenation. Mediastinal position varies in neonates with congenital diaphragmatic hernia (CDH), reflecting contralateral shift due to mass effect. We aimed to create and validate a postnatal measurement of mediastinal positioning using chest radiographs in neonates with CDH who require extracorporeal membrane oxygenation. Chart review identified neonates with CDH who required veno-arterial extracorporeal membrane oxygenation between 2017 and 2022. Mediastinal shift index (MSI) is the ratio of the distance between the venous cannula tip and the contralateral chest wall divided by the total width of the contralateral
Imaging of Mediastinal Masses New 2020 ACR Appropriateness Criteria® 1 Imaging of Mediastinal Masses American College of Radiology ACR Appropriateness Criteria® Imaging of Mediastinal Masses Variant 1: Clinically suspected mediastinal mass. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Radiography chest Usually Appropriate ☢ MRI chest without and with IV contrast Not Appropriate ☢☢☢☢ Variant 2: Indeterminate mediastinal mass on radiography. Next imaging study. Procedure Appropriateness Category Relative Radiation Level MRI chest without and with IV contrast Usually Appropriate O MRI chest without IV contrast Usually Appropriate O CT chest with IV contrast Usually Appropriate ☢☢☢ CT chest without IV contrast Usually Appropriate ☢☢☢ US chest Usually Not Appropriate O
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results The role of consolidation radiotherapy in primary mediastinal B-cell lymphoma (PMBCL) patients is controversial. The IELSG37 trial, a randomized non-inferiority study, aimed to assess whether irradiation can be omitted in PMBCL patients with complete metabolic response (CMR) after induction immunochemotherapy
Mediastinal lymph node dissection versus spared mediastinal lymph node dissection in stage IA non-small cell lung cancer presented as ground glass nodules: study protocol of a phase III, randomised, multicentre trial (MELDSIG) in China. Radical surgery including mediastinal lymph node dissection is the standard treatment for early-stage non-small cell lung cancer (NSCLC). About 50% lung nodules are pure ground glass or part-solid nodules, which are predominantly clinical stage IA NSCLC. Non-solid nodules rarely develop mediastinal lymph node metastasis. A phase III study was started in China to evaluate the non-inferiority in overall survival of spared mediastinal lymph node dissection compared with mediastinal lymph node dissection in stage IA NSCLC. A total of 1362 patients will be enrolled
Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial. To evaluate the role of different invasive and non-invasive mediastinal staging methods in patients with locally advanced non-small-cell lung cancer (NSCLC) treated with definitive chemoradiotherapy
PET-Based Risk Stratification in Primary Mediastinal B-Cell Lymphoma: A Comparative Analysis of Different Segmentation Methods in the IELSG37 Trial Patient Cohort. Standardizing tumor measurement on F-FDG PET is crucial for the routine clinical use of powerful PET-derived lymphoma prognostic factors such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG). The recent proposal of an SUV of 4 as a new reference segmentation threshold for most aggressive lymphomas may homogenize volume-based metrics and facilitate their clinical application. This study compared MTV and TLG in primary mediastinal B-cell lymphoma (PMBCL) patients estimated using an SUV of 4 and the current threshold at 25% of SUV Baseline PET metrics were evaluated in 501 PMBCL patients from the IELSG37 trial
Point-of-Care Ultrasound of a Pediatric Mediastinal Mass: A Case Report. Point-of-care ultrasound may be used for identification of thoracic pathology, including mediastinal masses. In this case report, we describe the case of an otherwise healthy 17-year-old boy who presented with generalized pruritis. Point-of-care ultrasound was useful in identifying a complex cystic and solid mediastinal mass
The Landmark Series: Advances in Preoperative Mediastinal Lymph Node Staging for Non-small Cell Lung Cancer (NSCLC). Accurate mediastinal staging is essential for determining the extent of lung cancer, predicting prognosis, and guiding treatment strategies. Current clinical guidelines recommend preoperative invasive mediastinal staging for most patients with potentially resectable lung cancer , as imaging modalities alone often lack sensitivity and specificity. Invasive mediastinal staging techniques are categorized into surgical (e.g., cervical mediastinoscopy, video-assisted thoracic surgery) and nonsurgical (i.e., minimally invasive) approaches. Although cervical mediastinoscopy has historically been the gold standard, minimally invasive techniques have gained prominence in recent decades
Incidence, outcome and risk factors of perioperative pulmonary complications in pediatric patients with mediastinal mass. This retrospective study was designed to identify the incidence, outcome and analyze risk factors of perioperative pulmonary complications in children with mediastinal mass so that to achieve the Enhanced Recovery After Surgery(ERAS). This study enrolled 247 pediatric patients undergoing mediastinal mass resection from June 2016 to June 2022. Medical record was reviewed for basic characteristics, presenting symptoms, preoperative imaging results, intraoperative data, and the occurrence of any pulmonary complications. Perioperative pulmonary complication was defined as intraoperative hypoxemia, postoperative respiratory failure, postoperative pulmonary infection
Primary mediastinal large B-cell Lymphoma: Biological features, clinical characteristics and current treatment strategies. Primary mediastinal large B-cell lymphoma (PMBCL) is a distinct subtype of B-cell lymphoma, representing a clinical and therapeutic challenge due to its unique presentation, histopathological features, and treatment response. It primarily affects young adults , with a significant female preponderance, and is characterized by a large anterior mediastinal mass that causes compressive symptoms. Despite its aggressive nature, PMBCL patients have a favorable prognosis, with a 5-year survival rate exceeding 80% when early remission is achieved through first-line therapy. Drawing on the significant scientific therapeutic advances over recent years, this review focuses
Clinical, genetic, radiological characteristics and management of mediastinal paragangliomas: a literature review and case series. Paragangliomas (PGLs) are neuroendocrine tumours (NETs) that arise from neural crest derived cells. Up to 40% of cases occur due to the presence of a pathogenic germline variant (PGV) in a known gene. Mediastinal PGLs are rare but are being diagnosed with increasing frequency. Treatment generally involves surgery but is complicated in mediastinal PGLs due to their anatomy. Here we will perform a literature review and discuss our experience with 18 such cases. Cases were identified via the Guy's and St Thomas' NHS Foundation Trust NET multidisciplinary team database. Tumours ranged in size from 0.6cx0.6cm to 6.8cmx4.9cm. 72.2% were associated with a PGV of SDHB
CT-Based radiomics nomogram of lung and mediastinal features to identify cardiovascular disease in chronic obstructive pulmonary disease: a multicenter study. To investigate the performance of two diagnostic models based on CT-derived lung and mediastinum radiomics nomograms for identifying cardiovascular disease (CVD) in Chronic Obstructive Pulmonary Disease (COPD) patients. Hospitalized
Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines. Primary mediastinal B-cell lymphoma (PMBCL) is a distinct subtype of large B-cell lymphoma with unique clinical, histopathological, and molecular characteristics. Despite its aggressive nature, PMBCL has a high cure rate when managed appropriately. Advances in the understanding of PMBCL biological characteristics, coupled